MTP-B1
MTP-B1 is a POLRMT MtPTAC degrader that activates mitochondrial ClpP. MTP-B1 recruits ClpP as a protease module to POLRMT, inducing ClpP-dependent proteolysis and reducing POLRMT protein levels. MTP-B1 induces ROS and apoptosis. MTP-B1 inhibits proliferation, clonogenic growth, oxidative phosphorylation pathway gene expression, and mitochondrial transcription. MTP-B1 inhibits tumor growth in xenograft tumor mouse models and reduces tumor Ki67. MTP-B1 can be used for pancreatic cancer research (pink: POLRMT inhibitor: HY-181072; blue: small molecule that activates mitochondrial protease ClpP: HY-189815).
For research use only. We do not sell to patients.
- Formula: C52H51F4N7O7
- Molecular Weight:962.00
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MIA PaCa-2 | DC50 |
187.2 nM
|
Half-maximal degradation of POLRMT in human MIA PaCa-2 pancreatic cancer cells after 24 hrs incubation by Western blot.
Half-maximal degradation of POLRMT in human MIA PaCa-2 pancreatic cancer cells after 24 hrs incubation by Western blot.
|
42819300 |
| ASPC1 | DC50 |
416.9 nM
|
Half-maximal degradation of POLRMT in human AsPC-1 pancreatic cancer cells.
Half-maximal degradation of POLRMT in human AsPC-1 pancreatic cancer cells.
|
42819300 |
| MIA PaCa-2 | IC50 |
5.08 nM
|
Antiproliferative activity against human MIA PaCa-2 pancreatic cancer cells by SRB assay.
Antiproliferative activity against human MIA PaCa-2 pancreatic cancer cells by SRB assay.
|
42819300 |
| ASPC1 | IC50 |
57.76 nM
|
Antiproliferative activity against human AsPC-1 pancreatic cancer cells by SRB assay.
Antiproliferative activity against human AsPC-1 pancreatic cancer cells by SRB assay.
|
42819300 |
| MIA PaCa-2 | DC50 |
8.81 nM
|
Half-maximal degradation of POLRMT in human MIA PaCa-2 pancreatic cancer cells after 7 days incubation.
Half-maximal degradation of POLRMT in human MIA PaCa-2 pancreatic cancer cells after 7 days incubation.
|
42819300 |
| MIA PaCa-2 | IC50 |
6.32 nM
|
Antiproliferative activity against human MIA PaCa-2 pancreatic cancer cells expressing negative control by SRB assay.
Antiproliferative activity against human MIA PaCa-2 pancreatic cancer cells expressing negative control by SRB assay.
|
42819300 |
| MIA PaCa-2 | IC50 |
94.15 nM
|
Antiproliferative activity against human MIA PaCa-2 pancreatic cancer cells overexpressing POLRMT by SRB assay.
Antiproliferative activity against human MIA PaCa-2 pancreatic cancer cells overexpressing POLRMT by SRB assay.
|
42819300 |
In Vitro
MTP-B1 (1 μM; 0-48 h) rapidly degrades POLRMT in MIA PaCa-2 cells, and the degradation persists after compound washout[1].
MTP-B1 (0.1-1 μM) reduces POLRMT immunofluorescence in MIA PaCa-2 cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MIA PaCa-2 cells
-
Concentration:0.5, 1, 5 μM
-
Incubation Time:24 h
-
Result:Retained potent POLRMT degradation activity in the initial screen;
-
Cell Line:MIA PaCa-2 and AsPC-1 cells
-
Concentration:125, 250, 500, 1000, 5000 nM
-
Incubation Time:24 h
-
Result:Dose-response assays gave a DC50 of 187.2 nM and Dmax of 98.18% in MIA PaCa-2 cells.
Showed a DC50 of 416.9 nM in AsPC-1 cells.
-
Cell Line:MIA PaCa-2 cells
-
Concentration:1 μM (time-course); 1 μM for 24 h followed by washout
-
Incubation Time:0, 4, 8, 16, 24 h; washout 24 h; 48 h
-
Result:MTP-B1 induced more than 50% POLRMT degradation within 16 h and near-complete degradation by 24 h.
A lower-molecular-weight POLRMT species appeared with degradation.
After washout, no appreciable POLRMT recovery was detected within 24 h, with only partial restoration at 48 h.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:mice with MIA PaCa-2 xenograft[1]
-
Dosage:25, 50, 100 mg/kg
-
Administration:i.v.; every other day; 25 days
-
Result:Achieved a tumor growth inhibition (TGI) of 70.1% at 100 mg/kg.
No significant body weight
loss.
Exhibited POLRMT degradation, reduced the
proliferation marker Ki67 and significant increased
TUNEL-positive apoptotic cells in tumors.
- RT-PCR
- Western Blot
- RNA extraction experimental
- Annexin V plus membrane-impermeant dye apoptosis staining
- ROS/oxidative-stress fluorescent staining
- Patient-Derived Orthotopic Xenograft (PDOX)
- Real Time qPCR (Q-PCR)
- Cell Viability Determination by MTT Colorimetric Assay
- Kinase activity and phosphorylation assays
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Ki-67 Immunostaining Proliferation Assay
- Patient-Derived Xenograft (PDX)
- Apoptosis Solutions
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Soft Agar Colony Formation Assay
- Protocol for Kinase activity and phosphorylation assays
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Intraperitoneal/Peritoneal Dissemination Xenograft
Parmacokinetics
| Species | Dose | Route | Cmax | AUC0-∞ | T1/2 |
|---|---|---|---|---|---|
| Mice[1] | 50 mg/kg | i.v. | 61966.67 ng/mL | 26,100.84 ng·h/mL | 3.47 h |
Chemical Information
-
Molecular Weight 962.00
-
Formula C52H51F4N7O7
-
SMILES
O=C(NCCCN(C1=C(CN(CC2=CC=CC(C#N)=C2)CC1)C(N3CC4=CC=C(C(F)(F)F)C=C4)=O)C3=O)CCN5CCN(C([C@H](OC6=CC(O7)=C(C=C6F)C(C8=CC=CC=C8C)=CC7=O)C)=O)CC5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)